MindMed completes Phase 2b trial enrollment for MM-120 in GAD treatment

MindMed Inc., a clinical-stage biopharmaceutical company, has announced the completion of enrollment and dosing in its Phase 2b study, MMED008, which focuses on the treatment ... Read More